Donaldson jumps as Facet acquisition plan and FY2026 outlook support shares
Donaldson (DCI) is rising after its latest fiscal Q2 2026 update outlined an $820 million all-cash deal to acquire Facet and reiterated FY2026 adjusted EPS of $3.93–$4.01. The company also highlighted 3.0% Q2 sales growth to $896.3 million, with Life Sciences up 16.2% and Industrial Filtration Solutions up 7.2%.
1) What’s driving DCI today
Donaldson shares are moving higher as investors refocus on the company’s most recent earnings update and capital-allocation pivot, including a definitive agreement to acquire Facet in an all-cash transaction valued at about $820 million. Management said the Facet deal is expected to close in the second half of fiscal 2026, positioning Donaldson to add fuel and fluid filtration exposure in mission-critical applications while potentially broadening its addressable market.
2) The key numbers investors are reacting to
In its fiscal second quarter 2026 release (quarter ended January 31, 2026), Donaldson reported sales of $896.3 million, up 3.0% year over year, driven by currency translation and pricing benefits that were partly offset by volume declines. Segment details showed Life Sciences sales up 16.2% and Industrial Filtration Solutions up 7.2%, while Aerospace and Defense sales fell 19.4% due to timing; management also noted Power Generation strength within Industrial Solutions.
3) Outlook and the main debate behind the move
Donaldson updated FY2026 adjusted EPS guidance to $3.93–$4.01 (down from $3.95–$4.11) and lowered its adjusted operating margin outlook to 16.0%–16.4% (from 16.2%–16.8%), citing gross margin pressure. Even with the trim, investors appear to be weighing the potential longer-term strategic value of the Facet acquisition and areas of demand strength against softer industrial volumes and near-term margin headwinds.
4) What to watch next
The next catalysts are updates on Facet closing timing, any incremental detail on integration or expected financial impact, and evidence that growth pockets (Life Sciences and Power Generation-related filtration) can offset cyclical weakness in On-Road and other industrial end markets. Management also said it does not anticipate additional share repurchases in the second half of fiscal 2026 due to the expected Facet closing, making organic execution and deal outcomes more important to near-term sentiment.